华盛顿大学的研究人员开发了GmPides,这是一个新颖的抗生素类,有效治疗小鼠抗药性巴氏感染。 Researchers at Washington University develop GmPcides, a novel antibiotic class that effectively treats drug-resistant staph infections in mice.

来自华盛顿大学医学院的研究人员开发了一种新的化合物GmpPides, 有效治疗小鼠的细菌感染, Researchers from Washington University School of Medicine developed a new compound, GmPcides, that effectively treats bacterial infections in mice, including rare, deadly "flesh-eating" illnesses. 这种新型的抗生素类针对的抗药性细菌,导致抗药性结扎感染、毒性休克综合症和其他严重疾病。 This novel antibiotic class targets gram-positive bacteria causing drug-resistant staph infections, toxic shock syndrome, and other severe illnesses. GmPPides在实验室实验和治疗小鼠腐烂的软组织感染方面显示了希望,对细菌细胞膜产生了重大影响,降低了抗药性。 GmPcides have shown promise in laboratory experiments and treating necrotizing soft-tissue infections in mice, with a significant effect on bacterial cell membranes and reduced likelihood of drug resistance.